Daiwa Securities Group Inc. Atea Pharmaceuticals, Inc. Transaction History
Daiwa Securities Group Inc.
- $27.1 Billion
- Q2 2025
A detailed history of Daiwa Securities Group Inc. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 242 shares of AVIR stock, worth $759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
242
Previous 242
-0.0%
Holding current value
$759
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding AVIR
# of Institutions
110Shares Held
48.9MCall Options Held
0Put Options Held
0-
Black Rock Inc. New York, NY9.12MShares$28.6 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$23.9 Million20.73% of portfolio
-
Tang Capital Management LLC San Diego, CA4.89MShares$15.4 Million1.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$15.3 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.49MShares$7.8 Million2.68% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $261M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...